Overview

Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
0
Participant gender:
Female
Summary
This phase II trial studies how well hyperthermic intraperitoneal chemotherapy works in improving quality of life in patients with stage IIIC-IV ovarian, fallopian tube, or primary peritoneal cancer. In hyperthermic intraperitoneal chemotherapy, the chemotherapy is warmed before being used and may help the drugs get into the cancer cells better, minimize the toxicity of the drugs on normal cells, and help to kill any cancer cells left over after surgery.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Wake Forest University Health Sciences
Collaborator:
National Cancer Institute (NCI)
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel
Criteria
Inclusion Criteria:

- Patients must have histologically or cytologically confirmed non-mucinous, epithelial
stage 3 or 4 carcinoma of the ovary, fallopian tube or peritoneum.

- Patients must not have received treatment for another malignancy within 3 years of
enrollment (patients who have received hormone therapy within 3 years of enrollment
are still eligible).

- Patients must have received at least 3 but not more than 6 cycles of
carboplatin-doublet based IV neoadjuvant chemotherapy and achieved at least stable
disease (radiographically confirmed) at the conclusion of this therapy.

- Age ≥ 18 years.

- Eastern Cooperative Oncology Group (ECOG) performance status =< 2

- Patients must have adequate organ and marrow function as defined below (within 30 days
of registration):

- Absolute neutrophil count >= 1,500/mcL (within 30 days of registration)

- Platelets >= 75,000/mcL (within 30 days of registration)

- Total bilirubin =< 1.5 mg/dL (within 30 days of registration)

- Creatinine clearance >= 50 mg/dL (within 30 days of registration)

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =<
3 x institutional upper limit of normal (within 30 days of registration)

- Alkaline phosphatase =< 3 x institutional upper limit of normal (within 30 days of
registration)

- The effects of HIPEC on the developing human fetus are unknown. For this reason, and
because carboplatin doublet therapy consists of pregnancy category D agents, women of
child-bearing potential must agree to use adequate contraception (hormonal or barrier
method of birth control; abstinence) prior to study entry and for the duration of
study participation. Should a woman become pregnant or suspect she is pregnant while
participating in this study, she should inform her treating physician immediately.

- Ability to understand and the willingness to sign an institutional review board
(IRB)-approved informed consent document.

Exclusion Criteria:

- Patients may not be receiving any other investigational agents.

- Patients with extra-abdominal metastatic disease.

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to carboplatin doublet agents.

- Uncontrolled intercurrent illness including, but not limited to ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

- Pregnant women are excluded from this study because carboplatin doublet therapy
consists of pregnancy category D agents with the potential for teratogenic or
abortifacient effects. Because there is an unknown but potential risk for adverse
events in nursing infants secondary to treatment of the mother with carboplatin
doublet therapy, breastfeeding should be discontinued.

- Men are excluded from participating due to the site specific nature of the disease
being studied.